Hydralazine hydrochloride - CAS 304-20-1
Catalog number: B0084-065607
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H8N4.HCl
Molecular Weight:
196.64
COA:
Inquire
Targets:
Others
Description:
Hydralazine HCl is a hydrochloride salt of hydralazine (Apresoline) that is a direct-acting smooth muscle relaxant with an IC50 of 1.9 mM.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-065607 100 g $298 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
Hydralazine hydrochloride
MSDS:
Inquire
InChIKey:
ZUXNZUWOTSUBMN-UHFFFAOYSA-N
InChI:
InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H
Canonical SMILES:
C1=CC=C2C(=C1)C=NN=C2NN.Cl
1.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.
Ruiz-Magaña MJ1, Martínez-Aguilar R1, Lucendo E1, Campillo-Davo D1, Schulze-Osthoff K2,3, Ruiz-Ruiz C1,4. Oncotarget. 2016 Mar 3. doi: 10.18632/oncotarget.7871. [Epub ahead of print]
Epigenetic therapies have emerged as promising anticancer approaches, since epigenetic modifications play a major role in tumor initiation and progression. Hydralazine, an approved vasodilator and antihypertensive drug, has been recently shown to act as a DNA methylation inhibitor. Even though hydralazine is already tested in clinical cancer trials, its mechanism of antitumor action remains undefined. Here, we show that hydralazine induced caspase-dependent apoptotic cell death in human p53-mutant leukemic T cells. Moreover, we demonstrate that hydralazine triggered the mitochondrial pathway of apoptosis by inducing Bak activation and loss of the mitochondrial membrane potential. Hydralazine treatment further resulted in the accumulation of reactive oxygen species, whereas a superoxide dismutase mimetic inhibited hydralazine-induced cell death. Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway.
2.Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.
Sharma KJ1, Rodriguez M1, Kilpatrick SJ1, Greene N1, Aghajanian P1. Hypertens Pregnancy. 2016 Feb;35(1):123-8. doi: 10.3109/10641955.2015.1117098. Epub 2016 Feb 24.
OBJECTIVE: To determine whether the incidence of hypotension or adverse fetal heart tracing (FHT) category change differed following antepartum administration of intravenous (IV) labetalol versus hydralazine.
3.Heart Failure Update: Outpatient Management.
Wojnowich K1, Korabathina R2. FP Essent. 2016 Mar;442:18-25.
Outpatient management of heart failure (HF) is aimed at treating symptoms and preventing hospitalizations and readmissions. Management is initiated in a stepwise approach. Blockade of the renin-angiotensin system is a cornerstone of therapy and should be started, along with beta blockers, as soon as the diagnosis of HF is made. Other drugs, including diuretics, aldosterone antagonists, hydralazine, and nitrates, may be added based on symptoms and American College of Cardiology/American Heart Association stage. Despite a great interest in and theoretical benefit of naturoceutical products in the mitigation of oxidative stress and HF progression, none has been proven to be beneficial, and concerns exist regarding their interactions with standard HF drugs. Other nonpharmacologic interventions, including sodium restriction, regular exercise, and/or cardiac rehabilitation, should be initiated at diagnosis. HF often is progressive, and clinicians should be aware of late stage management options, including implantable devices, cardiac transplantation, and hospice care.
4.Novel epigenetic-based therapies useful in cardiovascular medicine.
Napoli C1, Grimaldi V1, De Pascale MR1, Sommese L1, Infante T1, Soricelli A1. World J Cardiol. 2016 Feb 26;8(2):211-9. doi: 10.4330/wjc.v8.i2.211.
Epigenetic modifications include DNA methylation, histone modifications, and microRNA. Gene alterations have been found to be associated with cardiovascular diseases, and epigenetic mechanisms are continuously being studied to find new useful strategies for the clinical management of afflicted patients. Numerous cardiovascular disorders are characterized by the abnormal methylation of CpG islands and so specific drugs that could inhibit DNA methyltransferase directly or by reducing its gene expression (e.g., hydralazine and procainamide) are currently under investigation. The anti-proliferative and anti-inflammatory properties of histone deacetylase inhibitors and their cardio-protective effects have been confirmed in preclinical studies. Furthermore, the regulation of the expression of microRNA targets through pharmacological tools is still under development. Indeed, large controlled trials are required to establish whether current possible candidate antisense microRNAs could offer better therapeutic benefits in clinical practice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 2447-54-3 Sanguinarine

Sanguinarine
(CAS: 2447-54-3)

Sanguinarine caused cell death in a dose dependent manner in all neuroblastoma cell lines except SK-N-BE(2) with rates of 18% in SH-SY5Y and 21% in Kelly human ...

CAS 37988-18-4 LM 22A4

LM 22A4
(CAS: 37988-18-4)

LM22A-4 is a selective small-molecule partial agonist of TrkB with IC50 value of 47 nM. It can be used for neurological disease research. LM22A-4 can produce ne...

CAS 501104-16-1 Lalistat 1

Lalistat 1
(CAS: 501104-16-1)

Lalistat 1 is a lysosomal acid lipase inhibitor with IC50 value of 68 nM. It can block LAL-mediated lipid hydrolysis of acetylated LDL and reduce efflux of chol...

CAS 141626-36-0 Dronedarone

Dronedarone
(CAS: 141626-36-0)

Dronedarone is a Class III antiarrhythmic and a multi-channel blocker for atrial fibrillation. It blocks potassium, sodium, and calcium channels and also exhibi...

GBT-440
(CAS: 1446321-46-5)

GBT-440 is a substituted benzaldehyde compound that can modulate sickle hemoglobin (HbS) for treatment of disorders.

CAS 483-34-1 (-)-Isocorypalmine

(-)-Isocorypalmine
(CAS: 483-34-1)

(-)-Isocorypalmine is a alkaloid, as a metabolite of the isoquinoline.

CAS 938-73-8 2-Ethoxybenzamide

2-Ethoxybenzamide
(CAS: 938-73-8)

2-Ethoxybenzamide is a common analgesic and anti-inflammatory drug. It is used to reduce the fever, headaches, and other minor aches and pains. It is an ingredi...

CAS 216168-45-5 Probucol Disuccinate

Probucol Disuccinate
(CAS: 216168-45-5)

Probucol Disuccinate is the succinate ester form of probucol, which is a potent oxidant. Probucol inhibits the oxidantion of cholesterol in LDLs, and also lower...

CAS 1161233-85-7 BTZ043

BTZ043
(CAS: 1161233-85-7)

The new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets th...

CAS 265980-25-4 SCH 202676 hydrobromide

SCH 202676 hydrobromide
(CAS: 265980-25-4)

SCH 202676 hydrobromide is a reversible inhibitor of agonist and antagonist binding to G-protein-coupled receptors. It inhibits a variety of GPCRs including ade...

CAS 141400-58-0 PX-12

PX-12
(CAS: 141400-58-0)

PX-12 is an irreversible inhibitor of Trx-1 currently in clinical development as an antitumor agent. The research results suggest that the lowering of elevated ...

CAS 68497-62-1 Pramiracetam

Pramiracetam
(CAS: 68497-62-1)

Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. It is a more potent nootropic drug derived from...

CGP-75254A
(CAS: 199485-26-2)

CGP-75254A, a novel oral iron chelator, across Caco-2 cells in an attempt to model intestinal epithelial cell permeability in man. Studies predicted that absorp...

CAS 1217022-63-3 PTC-209 hydrobromide

PTC-209 hydrobromide
(CAS: 1217022-63-3)

Polycomb complex protein BMI-1 is a polycomb ring finger oncogene that regulates the p16 and p19 cell cycle inhibitor genes. It is necessary for efficient self-...

RUSKI-201 dihydrochloride

RUSKI-201 dihydrochloride is a sonic hedgehog acyltransferase (HHAT) inhibitor (IC50 = 0.20 μM) devoid of off-target cytotoxicity, and quantitative whole-proteo...

CAS 23047-14-5 Glibenclamide potassium salt

Glibenclamide potassium salt
(CAS: 23047-14-5)

Glibenclamide potassium salt is a salt form of Glibenclamide, a KATP channel blocker used for the treatment of type 2 diabetes. Glibenclamide binds to and inhib...

CAS 283159-90-0 Valifenalate

Valifenalate
(CAS: 283159-90-0)

Valifenalate(IR5885; Valiphenal), which is approved for application on high-value crops such as grapes, tomatoes and other vegetables, is effective against vari...

EML-425
(CAS: 1675821-32-5)

EML-425, a diazinane derivative, has been found to be a CBP/p300 inhibitor that could probably be significant in studies of human leukemia cells. IC50: 1.1 and ...

CAS 856676-23-8 Choline Fenofibrate

Choline Fenofibrate
(CAS: 856676-23-8)

Choline Fenofibrate is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipide...

CAS 84782-21-8 Cgp 8716

Cgp 8716
(CAS: 84782-21-8)

Cgp 8716 is a major metabolite of GP53,633 which is a basic non-steroidal anti-inflammatory agent Originated by Novartis.

Chemical Structure

CAS 304-20-1 Hydralazine hydrochloride

Quick Inquiry

Verification code

Featured Items